Outcome of Vitamin D supplementation alongwith the standard treatment in Lymphoma Patients.
Not Applicable
- Registration Number
- CTRI/2019/03/018211
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)All newly diagnosed patients with Hodgkin Lymphoma(HL) and Non Hodgkinâ??s Lymphoma(NHL)
2) Age group (7-80 yrs)
Exclusion Criteria
1) Patients who are not planned for any anticancer treatment.
2) Patients previously treated with chemotherapy/radiotherapy/surgery.
3)Patients having renal stone or Hypercalcemia ( more than 12 mg/dl) will not be given supplementation
4) Female patients with pregnancy or lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a)To study the association of baseline vitamin D level with Overall Response Rate(ORR) in patients with newly diagnosed lymphoma. <br/ ><br>b)To study the effect of vitamin D supplementation on Overall Response Rate (ORR) in the vitamin D deficient patients with newly diagnosed lymphoma. <br/ ><br>Timepoint: August 2018 to May 2020 <br/ ><br>
- Secondary Outcome Measures
Name Time Method a) To study the association of baseline vitamin D levels with Event Free Survival (EFS) in patients with newly diagnosed lymphoma. <br/ ><br>b) To study and compare chemotherapy toxicities in newly diagnosed lymphoma patients with and without vitamin D deficiency. <br/ ><br>Timepoint: August 2018 to May 2020